Skip to content
Screener

Ocular Therapeutix OCUL Total Liabilities & Equity

Total Liabilities & Equity at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$41.73B+9.2%
EyePoint, Inc. logo
EyePoint, Inc.EYPT
$228.19M-24.2%
KLR
Kalaris TherapeuticsKLRS
$109.81M+6.5%
Bausch + Lomb logo
Bausch + LombBLCO
$13.86B+0.2%
HRO
HarrowHROW
$419.54M+15.2%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$611.14M+23.5%

Other financials

Income statement

See full
Revenue$10.8M+0.8%
Gross profit$9.5M+0.2%
Operating income-$93.3M-46.0%
Net income-$88.6M-38.3%
EPS (diluted)-$0.40-5.3%

Balance sheet

See full
Cash & equivalents$666.7M+90.7%
Total debt$79.5M+4.2%
Total equity$581.6M+119%
Total assets$732.5M+80.5%

Cash flow

See full
Operating cash flow-$66.0M-47.7%
CapEx$4.7M+141%
Free cash flow-$70.7M-51.6%

Valuation

See full
Market cap$1.92B-11.7%
Enterprise value$1.33B-28.4%
P/S36.9×-1.5×

Profitability

See full
Gross margin87.2%-3.4pp
Operating margin-575.4%+1,233pp
Net margin-558.2%+1,493pp
FCF margin-463%+2,860pp

Returns & leverage

See full
Return on equity-68.6%+17.0pp
Debt / equity0.1×-0.2×
Current ratio14.8×+4.6×

Where this comes from

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Ocular Therapeutix’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 7:28 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-055256
Line itemMarch 31, 2026December 31, 2025
Commitments and contingencies (Note 14)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares issued or outstanding at March 31, 2026 and December 31, 2025, respectively
Common stock, $0.0001 par value; 400,000,000 and 400,000,000 shares authorized and 218,896,915 and 215,927,600 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively2222
Additional paid-in capital1,827,1871,811,311
Accumulated deficit(1,245,635)(1,157,023)
Total stockholders’ equity581,574654,310
Total liabilities and stockholders’ equity$732,529$808,057

Item 1. Financial Statements (unaudited)

FAQ

What is Ocular Therapeutix's total liabilities & equity?
Ocular Therapeutix (OCUL) reported total liabilities & equity of $732.53M in Q1 2026.
How has Ocular Therapeutix's total liabilities & equity changed year-over-year?
Ocular Therapeutix's total liabilities & equity increased by 80.5% year-over-year, from $405.92M to $732.53M.
What is the long-term trend for Ocular Therapeutix's total liabilities & equity?
Over 5 years (2020 to 2025), Ocular Therapeutix's total liabilities & equity has grown at a 25.3% compound annual growth rate (CAGR), from $261.86M to $808.06M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Ocular Therapeutix's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude